Efared Boubacar, Sidibé Ibrahim S, Gamrani Sana, El Otmani Ihsane, Erregad Fatimazahra, Hammas Nawal, Bennis Sanae, Chbani Laila, El Fatemi Hinde
1 Hassan II University Hospital, Fès, Morocco.
2 Sidi Mohamed Ben Abdellah University, Fès, Morocco.
Int J Surg Pathol. 2018 Oct;26(7):593-599. doi: 10.1177/1066896918767546. Epub 2018 Apr 9.
A subset of breast carcinomas harbors overexpression of the human epidermal growth factor receptor 2 (HER2). Fluorescence in situ hybridization (FISH) should be performed in breast carcinomas with equivocal HER2 immunostaining (immunohistochemistry [IHC] HER2 2+). The aim of our study is to investigate clinicopathologic factors associated with HER2 status in breast invasive carcinomas with IHC HER2 2+ through FISH analysis.
This is a retrospective study including the FISH analysis of 111 patients with invasive breast carcinomas with equivocal HER2 immunostaining.
The mean age was 49.51 ± 10.48 years, and invasive breast carcinoma of no special type was the most histological type in our study (96.4%). Most patients had tumors positive for hormones receptors (88.2% positive for estrogen receptor and 81.4% for progesterone receptor). On FISH, the HER2 amplification rate was 22.5%. There was no significant association of HER2 status with any clinicopathologic factors ( P > .05).
Our study shows that there are no reliable clinicopathologic factors to predict the HER2 status in breast tumors with equivocal HER2 immunostaining, supporting the necessary usage of FISH in such circumstances.
一部分乳腺癌存在人表皮生长因子受体2（HER2）过表达。对于HER2免疫染色结果不明确（免疫组织化学[IHC] HER2 2+）的乳腺癌，应进行荧光原位杂交（FISH）检测。我们研究的目的是通过FISH分析，调查IHC HER2 2+的乳腺浸润性癌中与HER2状态相关的临床病理因素。
这是一项回顾性研究，对111例HER2免疫染色结果不明确的乳腺浸润性癌患者进行FISH分析。
平均年龄为49.51±10.48岁，非特殊类型的乳腺浸润性癌是我们研究中最常见的组织学类型（96.4%）。大多数患者的肿瘤激素受体呈阳性（雌激素受体阳性率为88.2%，孕激素受体阳性率为81.4%）。FISH检测显示，HER2扩增率为22.5%。HER2状态与任何临床病理因素均无显著相关性（P>.05）。
我们的研究表明，对于HER2免疫染色结果不明确的乳腺肿瘤，没有可靠的临床病理因素可用于预测HER2状态，这支持在此类情况下有必要使用FISH检测。
